Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro (CLPT) disclosed a Form 4 for its Chief Operating Officer, Mazin Sabra. On 10/10/2025, 7,480 shares of common stock were withheld (Transaction Code F) to satisfy tax obligations upon the vesting of restricted stock at $26.11 per share. After the transaction, the reporting person beneficially owns 44,084 shares, held directly.
ClearPoint Neuro, Inc. filed a Form 144 reporting a proposed sale of 26,463 common shares through Morgan Stanley Smith Barney LLC on
R. John Fletcher, a director of ClearPoint Neuro, Inc. (CLPT), received 265 shares of the issuer's common stock on 10/01/2025 as payment of director fees under the company's Sixth Amended and Restated 2013 Incentive Compensation Plan and Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price on 9/30/2025 of $21.79 per share. After this transaction Fletcher beneficially owned 116,240 shares, held directly. The Form 4 was signed by power of attorney and filed on 10/02/2025.
ClearPoint Neuro, Inc. (CLPT) reported an insider issuance to director Pascal E. R. Girin: on 10/01/2025 the company issued 315 shares of common stock at a price equal to the closing market price on 9/30/2025, $21.79, as payment of fees under the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan and the Non-Employee Director Compensation Plan. Following the issuance, the reporting person beneficially owns 96,949 shares directly. The Form 4 was signed by an attorney under power of attorney and filed on 10/02/2025.
ClearPoint Neuro, Inc. filed a Form S-8 registration statement to register additional shares of its common stock for issuance under two employee equity plans: the Amended and Restated 2021 Employee Stock Purchase Plan and the Sixth Amended and Restated 2013 Incentive Compensation Plan. The filing incorporates by reference the company’s recent proxy statement, annual report, quarterly reports, and certain current reports, along with the existing S-8 registration statements for these plans. The document also lists the company’s charter and bylaw documents, legal opinions, consents, and power of attorney as exhibits, and is signed by the chief executive officer, chief financial officer, and all directors.
ClearPoint Neuro reported total revenue of $9.2 million for the quarter, up 17% from $7.9 million a year earlier, led by product revenue of $6.0 million (up 21%). Gross profit was $5.6 million with a 60% margin, slightly below prior-year margins. The company recorded a net loss of $5.8 million for the quarter (basic and diluted loss per share $0.21) and a six-month net loss of $11.9 million (EPS $0.42), driven by higher research and development, sales and marketing, and general and administrative expenses.
Liquidity strengthened to $41.5 million in cash and equivalents at June 30, 2025 after a registered direct equity sale that raised ~$3.3 million net and an initial note issuance that provided approximately $28.7 million net. The company entered a Note Purchase Agreement providing up to $105.0 million of potential notes (initial $30.0 million funded) secured by substantially all assets and carrying PIK interest and future revenue-sharing provisions; management states existing cash is sufficient for at least the next twelve months. Accumulated deficit totaled $203.2 million.